Nuformix PLC
LSE:NFX

Watchlist Manager
Nuformix PLC Logo
Nuformix PLC
LSE:NFX
Watchlist
Price: 0.2633 GBX -4.25% Market Closed
Market Cap: £5.6m

Relative Value

NFX doesn't have a meaningful market cap.

The Relative Value of one NFX stock under the Base Case scenario is hidden GBX. Compared to the current market price of 0.2633 GBX, Nuformix PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NFX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NFX Competitors Multiples
Nuformix PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Nuformix PLC
LSE:NFX
5.8m GBP 0 -1.5 -1.5 -1.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
US
Johnson & Johnson
NYSE:JNJ
530.7B USD 5.6 19.8 13.8 17
CH
Roche Holding AG
SIX:ROG
278.2B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP 5 30.8 20 29.3
CH
Novartis AG
SIX:NOVN
222.3B CHF 5 19.5 15.7 20.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17 11.8 13.7
US
Merck & Co Inc
NYSE:MRK
267.5B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
97.2B EUR 1.5 7.1 6.4 6.4
P/S Multiple
Revenue Growth P/S to Growth
UK
Nuformix PLC
LSE:NFX
Average P/S: 14.5
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
16.9
27%
0.6
US
Johnson & Johnson
NYSE:JNJ
5.6
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.5
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
5
8%
0.6
CH
Novartis AG
SIX:NOVN
5
5%
1
DK
Novo Nordisk A/S
CSE:NOVO B
5.6
5%
1.1
US
Merck & Co Inc
NYSE:MRK
4.2
4%
1
IE
E
Endo International PLC
LSE:0Y5F
94
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
FR
Sanofi SA
PAR:SAN
1.5
5%
0.3
P/E Multiple
Earnings Growth PEG
UK
Nuformix PLC
LSE:NFX
Average P/E: 23
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
38%
0.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
17
2%
8.5
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
7.1
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Nuformix PLC
LSE:NFX
Average EV/EBITDA: 47.9
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20
10%
2
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
1%
11.8
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Nuformix PLC
LSE:NFX
Average EV/EBIT: 102.8
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.3
23%
1.3
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4